Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Cancer - 1 Sept 2016

Ross Jeffrey S, Gay Laurie M, Wang Kai, Ali Siraj M, Chumsri Saranya, Elvin Julia A, Bose Ron, Vergilio Jo-Anne, Suh James, Yelensky Roman, Lipson Doron, Chmielecki Juliann, Waintraub Stanley, Leyland-Jones Brian, Miller Vincent A, Stephens Philip J

Abstract excerpt

BACKGROUND: Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)-targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Carcinoma, Lobular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Lymphatic Metastasis

Share to Molecular Targeted Therapy

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 27284958
DOI: 10.1002/cncr.30102

Genes

ERBB2
CDH1
CCND1
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.PMID 27284958Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.Semantic proximity Read ↗

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.Semantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity Read ↗

Concordance of genomic alterations between primary and recurrent breast cancer.Semantic proximity Read ↗

ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high‐risk characteristics by molecular expression profilingSemantic proximity Read ↗

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.Semantic proximity Read ↗

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.Semantic proximity Read ↗

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.Semantic proximity Read ↗

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Semantic proximity Read ↗

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.